India: Data Exclusivity - Its Interpretation and India

Last Updated: 7 January 2005
Article by Rahul Goel

The Intellectual Property Regime in India is in the final stages of ensuring compliance with the standards agreed in the World Trade Organization’s Agreement on the Trade Related Aspects of Intellectual Property Rights (‘TRIPS’). Much highlighted is the imminent amendment proposed to the Indian Patents laws. However, India’s TRIPs obligations are not only limited to ensuring its Patent Laws to conform with the TRIPs standards but also to provide adequate protection to that class of Intellectual property Rights (‘IPRs’) enumerated in Article 39 of TRIPs Agreement. This TRIPs provision owes its origin to Article 10bis of Paris Convention1, which provides for ensuring effective protection against unfair competition by protection of undisclosed information.

Companies involved in research and development (R&D) spend a considerable amount of time and money on innovation of new products. The protection available under Intellectual Property laws requires them to disclose the information publicly and later grants them exclusivity for a very limited period of time. The pharmaceutical companies research and generate pre-clinical and clinical trial data, which is imperative for endorsement of a pharmaceutical or medicinal product. The costs involved in generation of such test results are extremely high and form the basis of development and production of any new pharmaceutical drug. As per estimates, the time involved in getting approval after the grant of the patent, from the relevant drug controlling authorities and before the drug is finally introduced into the market, is around 12-13 years and average costs involved are USD 500 million2. In developing countries, it takes another 2-33 years before the drug is introduced. Thus, giving a drug or pharmaceutical manufacturer only 7-8 years (or may be even less than that) of effective Intellectual Property protection.

The R&D oriented pharmaceutical companies, for the purpose of regaining their investment, require protection for a particular period, during which competitors are not permitted to use research data submitted by a patentee or a manufacturer of new drugs. The innovator has proprietary rights over the clinical test data and other research data.4 Research data that is confidential and proprietary knowledge of the inventor/innovator or his licensee, is protected under Article 39.35 of the TRIPs Agreement.

Undisclosed information is recognized as a form of intellectual property in Article 39 of the TRIPS agreement. Article 39.3 of the TRIPS, requires WTO Member States to protect clinical test data submitted for the marketing approval or for registration purposes. The test data has to be protected against any "unfair commercial use". The term ‘unfair commercial use’ has not been defined anywhere in the text of the TRIPs Agreement, but an inference can be drawn from the negotiating history of Article 39.3 that testifies the contest between new drugs manufacturers and the generic drugs manufacturer. During the negotiation stages, it was strongly contended that a generic competitor should not benefit from relying on the research data of the innovator, made public during the process of securing patent registration and drugs approval, at least for a specific period of time.

Some countries provide for sui generis form of protection, whereby giving temporary right to use such data to the first applicant6. This curtails the practice of other manufacturers of similar products, on relying on test data of the first applicant. In other countries, authorities, at times, rely on the data submitted by the first applicant to approve the ensuing applications for similar products. For the purpose, it is to be proved that the physico-chemical components are similar to the product of the first applicant. This practice is more common while granting approval for generic pharmaceutical drugs. Data exclusivity in general prevents the Drug Controller from utilizing the original or innovator’s clinical trial data for a specific period. During this period no generic drugs would be approved based on the original test data. This kind of market protection may restrict the access to pharmaceutical drugs, mainly in developing and least developed countries. Since Article 39 has no time limit, it may lead to unlimited protection against generic application of un-patented drugs and chemical products.

The data protection, as also advocated by India, is different from patenting and both are distinct forms of protection. Protection of one right is independent of the other. The clinical test data, which forms a critical part in research and development of a pharmaceutical drug, is not protected by the way of patent. The protection of test data is provided under Article 39.3. It is also argued that the existing Official Secrets Act, is sufficient enough to provide protection to Undisclosed Information, as Drug Controller works within the ambit of the said act and there has not been any instance where the drug controller has misused his authority and power. It is further argued that neither the regulatory authorities nor the competitor uses the pre-clinical trial data or clinical trial data as generated by the first applicant.7

India, under the rapidly changing international trade scenario and immense lobbying of pharmaceutical companies, has been forced to assess its stand on Article 39.3. Unlike US and European Union, India’s stand and interpretation of Article 39.3 does not include market exclusivity to the innovator and does not create market protection. India is of the view that the said article only talks about the protection of test data against unfair use and nothing about data exclusivity, which is further interpreted to be same as market exclusivity. It is viewed that Data Protection is very different from data exclusivity. EU and US are of the opinion that article 39.3 also covers data exclusivity. Wherein they have adopted similar legislation to provide data exclusivity to innovator, the duration of which may exceed up to ten years in EU and five years in US. Since the main objective of Article 39.3 is to restrict and stop ‘unfair commercial use’ or unfair competition, it is vital to analyse ‘unfair competition’ as described by WIPO:

"The repression of unfair competition is not concerned with exclusive rights, but is directed against acts of competition contrary to honest practices in industrial or commercial matters, for example, in relation to undisclosed information (trade secrets)."8

The debate on Article 39.3 revolves around whether to include or to leave data exclusivity from the interpretation of the said article. On the analysis of the text of WIPO as mentioned above, it can be agued that repression of unfair competition does not advocate any kind of exclusive rights. Thus, the demand to give market exclusivity to pharmaceutical companies or the innovator on the basis of Article 39.3 would be very unfair. Moreover, the word ‘exclusivity’ is not mentioned anywhere in the Article. This Article also discusses protection of data against unfair commercial use. It is contended that the pressure from the multinational companies primarily based in EU and US, is against the spirit of Doha Declaration, where it was stated that, the TRIPS Agreement does not and should not prevent Members from taking measures to protect public health. It was further stated that the Agreement can and should be interpreted and implemented in a manner supportive of WTO Members’ right to protect public health and, in particular, to promote access to medicines for all.9 This declaration among others has more importance for developing and least developed countries, where generic drugs, compulsory licensing and parallel imports play a vital role as needed to enhance access and implement public heath policies.

On the other hand, the only concern as shown by the groups opposing, EU and US stand is, the extension of protection period beyond current 20 years protection period as granted under Patents Act or leading it to ‘ever-greening of patents’. The above-mentioned argument can be countered, taking in to account Poland’s legislative framework on data exclusivity. Poland though, providing for data exclusivity, calculates the period of protection from the first date of global registration of the patent. Thus restricting the period of protection in Poland. A similar kind of an approach, if adopted, can counter the fear of ever-greening of patents and can also resolve the debate related to data protection and data exclusivity. The exclusivity which otherwise would also be available on the grant of patent, would continue under data exclusivity. This would ensure that the time period of data exclusivity or protection not going beyond patent protection period. Alternatively, a ceiling can be set whereby it can be set that the time period of data exclusivity shall not be granted beyond patent protection. This is more closely related to the system as adopted by some of the EU members like Germany and Portugal.10

Article 39.3 advocates protection only for ‘new chemical entities’. ‘New chemical entities’ are not defined anywhere in the Article. It is left on the Member States to examine and define, what new chemical entities would be? Any alteration or rectification or modification in the current legislation would also involve changes within the scope of functioning of the Drug Controller.

Data Exclusivity (Article 39.3), in more concrete form, only seeks protection of the interests of the innovator and originator, against any unfair commercial use and provides a healthy platform to encourage investments and innovation for social benefit.


1 viewed on November 10, 2004.

2 Data Exclusivity – A TRIPS Dictated Supra-IP Protection Tool by A.D.Damodaran at viewed on November 04, 2004

3 "…a patented drug is introduced in the 17th year of the 20-year patent life…", Pharma Cos In Grip Of Feverish Debate On Data Exclusivity at viewed on November 04, 2004

4 TRIPS Article 39.3 (Protection of Undisclosed Data) A critical issue for the continued development of of safe and innovative medicines for patents) at viewed on November 22, 2004

5 Article 39.3 of TRIPS: "Members, when requiring, as a condition of approving the marketing of pharmaceutical or of agricultural chemical products that utilize new chemical entities, the submission of undisclosed test or other data, the origination of which involves a considerable effort, shall protect such data against unfair commercial use. In addition, Members shall protect such data against disclosure, except where necessary to protect the public, or unless steps are taken to ensure that the data are protected against unfair commercial use." Viewed on June 05, 2004.

6 viewed on November 22, 2004

7 Data protection not synonymous with granting EMRs, Govt tells drug cos, Harish Damodaran in Business Line at viewed on November 22, 2004

8 Pg 4 at, viewed in Jun’04.

9 World Trade Organisation,, viewed in Jun’04.

10 Pg 7 at, viewed in Jun 04

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.